MannKind Corporation announced a $50 million private placement led by Frazier Life Sciences, selling common stock and pre-funded warrants to institutional investors. The funds will support general corporate purposes, including a $45 million payment linked to the recent FDA approval of their drug Furoscix ReadyFlow™, an autoinjector for treating edema in heart failure and chronic kidney disease. The financing is expected to close around July 24, 2026, and MannKind plans to register the resale of these securities with the SEC. This capital raise aims to strengthen MannKind's position as it advances treatments for cardiometabolic and orphan lung diseases.
YieldMax ETFs declared weekly distributions for their Group 1 ETFs, with payment on October 15, 2026. The distributions vary by ETF, reflecting different distribution rates and 30-day SEC yields, ranging from about 23% to over 60%. These ETFs cover s...
Foresight Autonomous Holdings has signed a non-binding term sheet to acquire a 50.01% controlling interest in a company developing two data center projects in Warsaw and Wroclaw, Poland, with a combined planned capacity of 270 MW. This move aligns wi...
The Asia-Pacific sustainable data center market is projected to grow from $16.74 billion in 2025 to $57.18 billion by 2031, at a CAGR of 22.7%. Growth is fueled by rising demand for AI, cloud computing, and hyperscale infrastructure, prompting invest...
Holafly has introduced the Ultra Plan, a new global eSIM subscription that offers unlimited mobile data alongside health and wellness services, including 24/7 medical messaging, mental health sessions, nutrition and fitness coaching, and veterinary a...
Investec Bank plc, acting as advisor and broker for Gooch & Housego plc, sold 2,013 ordinary shares at a price of 1,230 per share on October 12, 2026. This transaction was disclosed under the Takeover Code, indicating a client-serving capacity trade ...
